SCHEMBL26264458

SCHEMBL26264458

O=C(O)C[C@H](NC(=O)c1cccc(-c2ccc(OC(F)(F)F)cc2)c1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SUCNR1 Q9BXA5 1/20 0.66
TMPRSS15 P98073 6/20 0.55
PRSS1 P07477 3/20 0.55
GPR132 Q9UNW8 1/20 0.51
ABL1 P00519 5/20 0.50
MME P08473 1/20 0.50
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ITGB3 P05106 1/20 0.47
ITGAV P06756 1/20 0.47
CTSL P07711 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
GCGR P47871 1/20 0.46
MMP12 P39900 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26263281 0.89 SUCNR1 (0.52) SUCNR1GPR132ABL1HPGDKDM4E
SCHEMBL26440578 0.85 ALDH1A1 (0.66) TMPRSS15PRSS1HPGDKDM4EALDH1A1
SCHEMBL26264447 0.83 KAT6A (0.51) SUCNR1TMPRSS15PRSS1
SCHEMBL26264461 0.79 SUCNR1 (1.00) SUCNR1ABL1
SCHEMBL3745780 0.77 AURKA (0.67) ABL1SMN1; SMN2
SCHEMBL3995770 0.77 FPR2 (0.63) SUCNR1GPR132MMEITGB3CTSS
SCHEMBL26264367 0.76 SUCNR1 (0.71) SUCNR1TMPRSS15PRSS1
SCHEMBL3995775 0.76 MMP12 (0.62) SUCNR1ALDH1A1ITGB3ITGAVMMP12
SCHEMBL6609651 0.74 HDAC8 (0.51) SUCNR1
SCHEMBL20545896 0.74 CTSA (0.52) SUCNR1MMESMN1; SMN2MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183776-A2 TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION NEW YORK UNIVERSITY (US) 2023-09-28 WO disclosed
US-20230293504-A1 TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION UNIV NEW YORK (US) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293504-A1 TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION SUCNR1, SYNGR2, TSPO SUCNR1 1/4885TMPRSS15 1562/4885PRSS1 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.